



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Skeletal energy homeostasis

**Citation for published version:**

Oldknow, K, Roberts, F, Lovdel, A, Farquharson, C, Morton, N, MacRae, V & Cawthorn, W 2017, 'Skeletal energy homeostasis: a paradigm of endocrine discovery', *Journal of Endocrinology*, vol. 234, no. 1. <https://doi.org/10.1530/JOE-17-0147>

**Digital Object Identifier (DOI):**

[10.1530/JOE-17-0147](https://doi.org/10.1530/JOE-17-0147)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

Journal of Endocrinology

**Publisher Rights Statement:**

This is the Authors Accepted Manuscript as Accepted by the Journal of Endocrinology on 28th April 2017

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



# **Skeletal energy homeostasis - A paradigm of endocrine discovery**

Karla J Suchacki<sup>1</sup>, Fiona Roberts<sup>2</sup>, Andrea Lovdel<sup>1</sup>, Colin Farquharson<sup>2</sup>, Nik M Morton<sup>1</sup>, Vicky E MacRae<sup>2</sup> and William P Cawthorn<sup>1</sup>.

<sup>1</sup> The Queen's Medical Research Institute, The University of Edinburgh, 47 Little France Crescent Edinburgh EH16 4TJ

<sup>2</sup> The Roslin Institute, The University of Edinburgh, Easter Bush, Midlothian, EH25 9RG

Karla J Suchacki – [ksuchack@exseed.ed.ac.uk](mailto:ksuchack@exseed.ed.ac.uk)

Short title - Skeletal energy homeostasis

Keywords: Marrow adipose tissue, metabolism, bone, osteoblast, pancreas

Word count: 5641

## **Abstract**

Throughout the last decade, significant developments in cellular, molecular, and mouse models have revealed major endocrine functions of the skeleton. More recent studies have evolved the interplay between bone-specific hormones, the skeleton, marrow adipose tissue, muscle and the brain. This review focuses on literature from the last decade, addressing endocrine regulation of global energy metabolism via the skeleton. In addition, we will highlight several recent studies that further our knowledge of new endocrine functions of some organs; explore remaining unanswered questions; and, finally, we will discuss future directions for this more complex era of bone biology research.

## **Introduction**

Bone has long been regarded as an organised collection of inert calcified structures that facilitate the motility of land animals. The skeleton's mass and composition provides vital organ protection, a niche for haematopoiesis, and allows for weight-bearing motion (Guntur and Rosen 2012; Oldknow, et al. 2015). To facilitate these classical functional roles, and to maintain bone integrity, there is a continuous homeostatic adjustment of the skeletal architecture and composition. Central to this adjustment is the highly regulated interplay of two distinct bone cell types, the osteoblast, and the osteoclast, which have opposing functions (Crockett, et al. 2011).

Osteoblasts comprise 5% of all bone cells and facilitate the formation of bone (Florencio-Silva, et al. 2015). Mature osteoblasts synthesise and release type 1 collagen, which forms the majority (85-90%) of the organic matrix of the bone (Karsenty, et al. 2009). Osteoblasts that

become embedded in the bone matrix undergo terminal differentiation, giving rise to osteocytes – the most abundant skeletal cell type (90% of total bone cells) (Dallas and Bonewald 2010). These immobilised cells are ideally suited to perform the function of translating mechanical strain into biochemical signals in order to regulate bone composition (Sugiyama, et al. 2010)(Figure 1). The bone itself is a dynamic organ that is constantly being remodelled. This is possible due to the unique function of osteoclasts, which mediate destruction (resorption) of the bone tissue in which they reside (Holtrop and King 1977). The biphasic action of osteoblasts and osteoclasts enables bone modelling and remodelling. Bone modelling occurs throughout the lifespan, allowing the bone to adapt altered stresses and strains put on it (e.g. the tennis players serving arm), whereas, bone remodelling (maintenance) occurs when the resorbed bone is completely replaced by new bone (Hadjidakis and Androulakis 2006). The regenerative process of a structure that contributes to such a large proportion of the body mass (approximately 15% men and 10% in women) requires an abundance of proteins to be synthesised and secreted. It is therefore plausible that a high energetic cost is associated with these diverse skeletal functions (Karsenty and Ferron 2012; Vaananen, et al. 2000).

From an evolutionary perspective, bones likely represent a strongly selected survival factor that permitted enhanced movement to allow scavenging, survive injury and therefore the survival of the organism. However, it is now clear that part of the selection process for bones involves its integral role in the endocrine control of whole-body energy metabolism (Guntur and Rosen 2013). One example of the poorly understood metabolic functions of the skeleton is the presence of adipose tissue within the bone marrow – referred to as marrow adipose tissue (MAT). Accounting for approximately 10% of the total fat mass in healthy humans, the

function of MAT and its association with bone-specific cells, namely osteoblasts, osteocytes and osteoclasts, remains unknown. Here we focus on recent discoveries that explain the endocrine functions and molecular mechanisms linking bone (inclusive of MAT and muscle) and energy expenditure.

## **Bone as an endocrine organ**

In addition to its structural role, bone is a well-recognised target for endocrine function. This is exemplified by the orchestrated inter-organ regulation of phosphate, which involves the parathyroid glands, kidneys, and intestines facilitating homeostatic maintenance of phosphate, in the mineralisation of bone extracellular matrix (Karsenty and Olson 2016). Implicit to the theory of homeostatic control is reciprocal crosstalk between the bone and these organs (Ramsay and Woods 2014). Indeed, the skeleton acts not only as an endocrine target but also as an endocrine organ with possible roles in the hormonal modulation of systemic energy homeostasis.

### **I) Osteocalcin**

Also known as BGP (bone Gla-protein), osteocalcin (OCN) is the most abundant osteoblast-specific non-collagenous protein. OCN is initially synthesised by the osteoblast as a pre-pro-molecule and is commonly used as a serum marker of bone formation (Brown, et al. 1984). OCN exists in the general circulation in fully carboxylated, partially carboxylated and completely uncarboxylated forms (Cairns and Price 1994; Plantalech, et al. 1991; Schilling, et al. 2005; Vergnaud, et al. 1997). Uncarboxylated OCN is formed when carboxylated OCN in the bone extracellular matrix is decarboxylated by the acidic pH (4.5) in osteoclastic resorption

lacunae. Uncarboxylated OCN promotes  $\beta$ -cell proliferation, insulin secretion, peripheral insulin sensitivity, energy expenditure and impacts memory and male fertility (Lee, et al. 2007; Oury, et al. 2013; Oury, et al. 2011). Recently a role for OCN in muscle function has been demonstrated. OCN levels doubled during endurance exercise in young adult wild-type (WT) mice, decreased significantly prior to or at mid-life, and OCN failed to increase during exercise in older mice. Importantly equivalent decreases in circulating OCN levels were observed in female rhesus monkeys and humans (Mera, et al. 2016a). OCN administration was sufficient to reverse the age-induced decrease in exercise capacity in mice. Specifically, in 15-month-old mice, injections of OCN raised circulating OCN levels more than 4-fold and allowed these mice to run for the same time and distance as 3-month-old mice. Moreover, under-carboxylated OCN promoted uptake and subsequent catabolism of glucose and fatty acids in myofibres (Mera et al. 2016a; Mera, et al. 2016b). These nutrients, in turn, facilitate physical adaptation to exercise, whilst concurrently promoting the exercise-induced release of interleukin-6 (IL-6) from skeletal muscle. IL-6 further drives the production of bioactive OCN, supporting the hypothesis of a bone-muscle feed-forward axis. Thus, in addition to its postulated role in glucose and weight homeostasis (Oldknow et al. 2015), OCN further contributes to the regulation of energy metabolism, through effects on skeletal muscle. This supports the hypothesis that insulin signalling mediates the link between bone remodelling, and whole body energy expenditure, and points towards a key role for the osteoblast in this relationship (Huesa, et al. 2014).

## **II) NPP1 and PHOSPHO1**

In order to further increase our knowledge of the skeletons' endocrine links with energy expenditure, the role of bone mineralisation factors such as

phosphoethanolamine/phosphocholine phosphatase 1 (PHOSPHO1); ectonucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) have been addressed. NPP1, encoded by the *Enpp1* gene in mice, is highly abundant in the plasma membrane (external side) and mineral-depositing matrix vesicles of the osteoblast (Mackenzie, et al. 2012). NPP1 generates inorganic pyrophosphate (PPi) through the hydrolysis of nucleotides (ATP). PPi potently inhibits hydroxyapatite crystal formation in tissues capable of mineralisation (bone, soft tissue), and acts as a precursor for inorganic phosphate (Pi) (Buckley, et al. 1990; Mackenzie et al. 2012). NPP1 regulates glucose homeostasis via suppression of insulin receptor signalling in various tissues, including adipose, bone, and muscle (Mackenzie et al. 2012; Maddux, et al. 1995). NPP1 binds to and inhibits insulin-induced receptor conformational changes and is a potential pathogenic contributor to insulin resistance (Huesa et al. 2014). This concept is supported by the phenotype of *Enpp1* ablated mice, which display improved glucose homeostasis and resist obesity-associated dysfunction in response to high-fat diet feeding (Huesa et al. 2014). Thus, NPP1 plays multifaceted roles in normal physiology, including the regulation of calcium and phosphate homeostasis, inhibition of soft tissue mineralisation, maintenance of skeletal function and structure regulation of insulin signalling and energy homeostasis.

The bone-specific phosphatase PHOSPHO1 is a member of the large haloacid dehalogenase (HAD) superfamily of Mg<sup>2+</sup> dependent hydrolases (Roberts, et al. 2004). PHOSPHO1 is active inside the osteoblast-derived matrix vesicle, where it scavenges Pi from matrix vesicle membrane phospholipids to promote intravascular hydroxyapatite deposition. Recent studies have identified novel roles of this bone-derived factor in energy homeostasis. Mice with *Phospho1* ablation exhibit a decreased body size and protection against both obesity and diabetes, regardless of carboxylation status of OCN (Chambers, et al. 2015; Dayeh, et al. 2016; Oldknow, et

al. 2013; Sayols-Baixeras, et al. 2016); however, the mechanisms conferring this metabolic-protective phenotype remain to be determined.

### III) PPAR $\gamma$

The transcription factor PPAR $\gamma$  is critical for differentiation of adipocytes and maintenance of the adipogenic phenotype. This is achieved via directing lineage commitment of marrow mesenchymal stem cells from an osteoblast-fate and towards that of adipocytes (Lecka-Czernik 2010). PPAR $\gamma$  insufficiency in mice results in decreased adipose tissue and increased bone mass via inhibition of osteoclastogenesis and bone resorption (Akune, et al. 2004). It remains unclear whether increased bone mass is a result of altered lineage commitment of bone marrow stem cells or an indirect effect through the modified function of adipose tissue. Alternatively, both direct and indirect mechanisms could account for the bone mass phenotype: PPAR $\gamma$  disruption in adipose tissue (*i.e.* lipodystrophic disease) resulted in increased osteoblast activity and concomitant increased bone formation. The mechanisms by which PPAR $\gamma$  regulates bone is not clear since mouse models of bone-specific PPAR $\gamma$  conditional knockouts have not been investigated to date (Cao, et al. 2015). To add further complexity, PPAR $\gamma$  deletion in other tissues causes profound effects on bone, further complicating investigative efforts. Osteoblast selective PPAR $\gamma$  deletion in mice (using PPAR(fl/fl):Col3.6-Cre) completely abolished adipogenesis, with the bone phenotype of increased osteoblastogenesis reflected in primary bone marrow culture and in isolated bone-marrow stem cells. The pivotal role of PPAR $\gamma$  is situated at the bifurcation of lineage commitment of bone and adipocytes, suggesting that therapeutic manipulation may help to manage obesity-related conditions and orthopaedic health (Lecka-Czernik 2010). For example, rosiglitazone (an insulin-sensitising thiazolidinedione) activates PPAR $\gamma$  and effectively treats T2DM by promoting insulin sensitivity. However, rosiglitazone use comes at a cost of



increased fracture risk consistent with increased adipogenesis and reduced osteoblastogenesis. With a promise for the effective management of T2DM, further work must continue to determine and thus avoid, any negative bone-phenotype associated with thiazolidinedione use (Fukunaga, et al. 2015).

#### **IV) Unexplored Candidates**

In light of the newly identified function of bone in energy metabolism, it is of interest to review the evidence for substrate utilisation in bone cells types. Overexpression of the glucose transporter Glut1 in osteoblasts enhances osteoblast differentiation and bone formation (Wei, et al. 2015). Assessment of glucose utilisation by the skeleton *in vivo*, using uptake of positron-emitting <sup>18</sup>F-fluorodeoxyglucose ([<sup>18</sup>F]-FDG), revealed greater glucose uptake in bone than in classical glucose storage and utilisation organs such as the liver, muscle and white adipose tissue (WAT) (Zoch, et al. 2016). Furthermore, skeletal [<sup>18</sup>F]-FDG uptake was greater in young than in older mice, which may be due to the rapid bone formation in young mice. Intriguingly, insulin administration significantly increased skeletal accumulation of [<sup>18</sup>F]-FDG, whilst insulin receptor-deficient and obese mice had reduced uptake (Zoch et al. 2016). These findings suggest that the skeleton is a preferential and significant site of glucose uptake that is regulated by insulin and global metabolism.

#### **Bone and adipose tissue**

In times of a positive energy balance (i.e. energy intake > energy expenditure) WAT stores excess energy as triacylglycerol (TAG) and releases fatty acids (FA) and glycerol to be used for  $\beta$ -oxidation or gluconeogenesis during negative energy balance, respectively (Cahill 2006;

Rosen and Spiegelman 2014). In addition to the role of adipose tissue in energy storage and release, adipose tissue also provides vital structural/mechanical protection for organs (e.g. the eye fat, pad, toes, and heel) (Rosen and Spiegelman 2014) and offers a critical thermoprotective layer against low ambient temperatures.

Discovery of adipose-derived circulating factors such as adipisin, TNF- $\alpha$ , leptin and adiponectin (Badman and Flier 2007; Rosen and Spiegelman 2014) defined adipose tissue as a bona fide endocrine organ. Through the release of these 'adipokines', WAT can exert diverse systemic effects, not only on energy homeostasis but also on other aspects of physiology such as blood pressure, immune function, and fertility (Michalakis, et al. 2013). Thus, despite its association with metabolic diseases, WAT performs many essential physiological functions. Indeed, in the absence, and/or the redistribution of adipose tissue (lipodystrophy), patients develop insulin resistance, hyperglycemia, hypertriglyceridemia, hepatic steatosis, and polycystic ovary syndrome underscoring the importance of adipose formation for normal physiological function (Cortes and Fernandez-Galilea 2015).

In contrast to white adipocytes, brown adipose tissue (BAT) is specialised for heat generation by non-shivering thermogenesis. Brown adipocytes, unlike white adipocytes, have an enrichment of mitochondria that express uncoupling protein-1 (UCP-1). This protein uncouples the respiratory chain, allowing protons to pass from the inner-membrane space to the mitochondrial matrix without passing through ATP synthase. This causes a futile cycle: oxygen is consumed to pump protons, but the resulting chemi-osmotic gradient generates no ATP and instead results in the dissipation of energy as heat (Nubel and Ricquier 2006). BAT is developmentally distinct to WAT, deriving from a distinct lineage that is shared

with skeletal muscle (Rosen and Spiegelman 2014). BAT activity is relatively high in small mammals and in newborn humans, whereas BAT in adult humans is less active and is situated deep within the neck and superclavicularly region. Nevertheless, BAT in adult humans remains cold-responsive, as exemplified in Scandinavian workers exposed to chronic cold (Huttunen, et al. 1981). Similarly, prolonged cold exposure in rodents has shown to alter WAT cells by developing a brown fat-like morphology. These cells have been named “beige” adipocytes, with a gene expression pattern overlapping but distinct to that of classical BAT (Rosen and Spiegelman 2014; Wu, et al. 2012).

Whilst these adipose sub-types have received extensive research focus, the MAT within the marrow cavity of the skeleton has been largely ignored. Concurrent with the emergence of the field of skeletal energy homeostasis, the research into the form and function of MAT has begun to expand. Postnatally, MAT forms at distal skeletal sites, including the tailbone, hands, and feet in mice and humans (Scheller and Rosen 2014). Throughout life, MAT (yellow marrow) continues to form in areas of the haematopoietic marrow (red marrow) until almost the entirety of the appendicular skeleton is converted into yellow marrow by the age of 20 in humans (Moerman, et al. 2004); however, red marrow persists in the axial skeleton, only declining with advanced age (Justesen, et al. 2001). Marrow adipocytes are derived from a distinctive progenitor cell that expresses osterix, Prrx1, LepR, and Gremlin1 (Chen, et al. 2014). Thus, marrow adipocytes may be highly related to osteoblast precursors and play a role in bone maintenance and skeletal energy (Liu et al., 2013; Mizoguchi et al. 2014).

MAT consists of two subtypes: constitutive MAT (cMAT) and regulated MAT (rMAT). cMAT is found predominantly in the distal skeleton, giving the bone marrow a yellow appearance

(Scheller, et al. 2015). In contrast, rMAT develops much later than cMAT, in the proximal skeleton, hip, ribs and lumbar/thoracic vertebrae postnatally and consists of adipocytes interspersed with red marrow. rMAT is not necessarily formed in a normal developmental/physiological manner, instead, rMAT seems to reflect adverse stimuli or disease states (Pichardo, et al. 2007; Rosen and Spiegelman 2014).

Many questions remain regarding the formation and function of MAT. In animal models, MAT increases in response to the contrasting interventions of calorie restriction (CR) and high-fat diet feeding (Cawthorn, et al. 2014; Devlin, et al. 2010; Doucette, et al. 2015). Similarly, humans with anorexia nervosa show MAT expansion (Misra and Klibanski 2013). Thus, does MAT, like WAT, play a role in regulating systemic energy homeostasis. Consistent with this possibility, is the suggestion that MAT may function as an energy reservoir for ectopic lipid, protecting skeletal osteoblasts from lipotoxicity (Gunaratnam, et al. 2014), as well as secreting FA, cytokines (IL-6/1 $\beta$  and TNF- $\alpha$ ) (Caers, et al. 2007) and adipokines (leptin and adiponectin) (Cawthorn et al. 2014; Rosen, et al. 2009). Moreover, there is often a relationship between bone loss and MAT expansion, which can coincide during ageing, osteoporosis, elevated glucocorticoids and cancer treatments. This further suggests a close relationship between bone-specific cells and marrow adipocytes (Georgiou, et al. 2012; Moerman et al. 2004).

## **The Diseased State**

The skeleton and associated bone-secreted factors provide a complex endocrine system that is finely orchestrated with other organs including the gut, brain, liver and kidney to ensure homeostatic balance and health. Indeed, bone-associated proteins act as a bridge to link

complex pathways that bring together bone turnover, mineralisation, mineral and metabolic homeostasis. When these pathways become dysregulated, affected individuals may suffer from bone, muscle, and adipose pathology (Figure 2).

#### **I) Multiple myeloma and myeloma bone disease:**

In the instance of multiple myeloma, affected individuals with myeloma bone disease (MBD) may experience altered bone metabolism, as a consequence of myeloma cells colonising the bone marrow (Walker, et al. 2014; Xi, et al. 2016). The pathophysiology of MBD is characterised by an imbalance in osteoblast and osteoclast activity. The resultant disruption of bone turnover is due to two distinct mechanisms. Firstly, engrafted myeloma cells are capable of secreting osteoclast-activating factors including, but not limited to, IL-6, IL- $\beta$ , TNF $\alpha$  and parathyroid hormone-related protein. Secondly, these engrafted cells can also interact with bone marrow microenvironment-regulating cells to further encourage secretion of osteoclast-activating factors (Roodman 2010; Terpos, et al. 2014). By orchestrating this two-pronged “attack”, myeloma cells increase osteoclastic bone resorption. Further, several molecular mechanisms have been attributed to promoting osteoblastic reduction within MBD: Wnt-antagonists Dickkopf-1 (DKK1), runt-related transcription factor 2 (Runx2), secreted frizzled related protein-2 (sFRP-2), transforming growth factor-beta (TGF- $\beta$ ), heparanase and hepatocyte growth factor (HGF) (Xi et al. 2016).

Such mechanisms, which compromise the normal physiological bone environment, are likely linked to energetic costs and wider metabolic consequences to the individual. Indeed, energy is expended upon the synthesis and secretion of an abundance of proteins required in the bone destruction process orchestrated by osteoclasts. Furthermore, in advanced disease states lytic

regions co-localise with elevated osteoclast activity and depressed osteoblastic activity. In accordance, the greater degree of bone acidification in osteoclastic resorption lacunae provides the conditions required to liberate the hormonally active form of OCN from the bone matrix via decarboxylation. An inverse correlation of serum decarboxylated OCN levels and the severity of MBD are reported in the literature (Bataille, et al. 1990). Furthermore, hypercalcemia is present at the site of bone lesions due to increased osteoclastic activity. This increased bone endocrine function represents changes to normal bone homeostasis and wider systemic and metabolic effects associated with the previously discussed roles of decarboxylated circulating OCN (i.e. increased insulin sensitivity, increased pancreatic  $\beta$ -cell proliferation, enhanced adipocyte secretion, and reduced insulin resistance; see Figure 3).

Improved understanding of the pathogenesis of MBD has led to the identification of novel therapeutic targets. DKK1 is a key regulatory factor in the normal development of bone in adulthood, acting to inhibit osteoblastogenesis and promote differentiation of mesenchymal stem cells towards adipocytes by suppressing Wnt/beta-catenin signalling. It can be hypothesised that the associated endocrine function of the increased MAT serves to propagate myelomagenesis and tumour growth, with elevated adipocyte numbers giving secretion of free fatty acids, signalling molecules (e.g. leptin, adiponectin) and myeloma-supportive adipokines (e.g. IL-6, TNF $\alpha$ ). A recent study revealed that blocking of DKK1 activity (or, alternatively, the addition of DKK1 antibody) resulted in a decrease of osteolytic bone disease, with a restoration of increased osteoblast activity and decreased myeloma tumour burden (Qiang, et al. 2008). The bi-directional signalling of myeloma cells and bone cells requires further investigation to determine the impacts of these interactions on bone homeostasis and tumour growth. Despite accelerated interest in the field, to date MBD (and multiple myeloma)

remain incurable: it is imperative that future work is conducted to further elucidate the molecular mechanisms underlying the disruption of the bone marrow microenvironment within the framework of this complex and multifactorial disease such that novel drugs may become a feasible reality for targeted therapy for the MBD patient.

## **II) Diabetes:**

Globally, 642 million adults are predicted to have diabetes by 2040 (Atlas 2016). The diabetic complication of fragility fractures is of increasing importance, representing an undeniably large burden for health-care systems of the world. The burden of diabetic-fracture can also be considered at the individual level: fracture healing necessitates three energetically costly processes including inflammation, repair, and remodelling (Regard, et al. 2012). It is conceivable that the associated energetic cost of this exerts a direct effect on global energy metabolism of the affected individual, although to date no established link of fracture burden and energy metabolism has been acknowledged.

In type 1 diabetes mellitus (T1DM), bone mineral density (BMD) – the gold standard measure for the determination of fracture risk - is decreased, a product of decreased osteoblastogenesis and increased osteoblast death (Coe, et al. 2011; McCabe 2007). Conversely, BMD is increased in type 2 DM (T2DM), yet in both T1DM and T2DM patients have a significantly higher fracture risk as a complication of diabetic bone disease, compared to the general public (Janghorbani, et al. 2006). This indicates a wider role of under-appreciated and undefined pathophysiological mechanisms responsible for diabetes-associated bone fragility and highlights the shortcomings of our modern day fracture-risk assessment techniques. It is likely that many T2DM patients of high fracture risk go unidentified prior to fracture incidence,

owing to the higher BMD associated with this class of diabetes. It remains possible that the physiological paradox of elevated BMD coinciding with increased fracture risk could well be explained by the higher prevalence of fall-associated trauma amongst diabetic patients (Gregg, et al. 2002; Schwartz, et al. 2002). However, it is likely that the pathophysiological mechanisms that underlie bone fragility in diabetic patients are of greater complexity than initially anticipated: even when studies include falls and associated risk factors, the association between diabetes and increased fractures remains inconclusively explained (Schwartz et al. 2002).

Suggested mechanisms of diabetic fractures include complications with hyperglycaemia, oxidative stress, and glycation end-product accumulation, which compromises the properties of collagen – the most abundant of the bone proteins (Napoli, et al. 2016). Furthermore, diabetes is associated with declining renal function, associated with lower BMD, and microvascular complications, which limit blood flow to the bone. Consequently, bones have decreased exposure to circulating bioactive hormones, including OCN, which may further contribute to skeletal fragility. These factors indicate there is a poorer quality of the bone such that there is increased fracture risk for both T1DM and T2DM, despite differences in BMD between these cohorts.

### **III) Obesity and Anorexia:**

Our knowledge of the pathogenicity of T2DM and bone disease is further complicated by the frequent overlap of T2DM with obesity. Indeed, a long-held concept is that obesity protects against fracture risk by increasing loading of the skeleton. Increased mechanical strain in obesity is sensed and translated by osteocytes, increased BMD. However, whilst seemingly



logical, this concept has recently been debunked: obesity itself is an independent risk for fracture owing to compromised quality of bones, despite non-compromised BMD (Johansson, et al. 2014; Palermo, et al. 2016). This confounds our attempts to understand diabetes-specific endocrine mechanisms underlying diabetic-associated skeletal fragility.

Obesity further manifests bone disease through mechanisms affecting metabolism. Since both marrow adipocytes and osteoblasts likely derive from a common progenitor within the BM stroma (Chen et al. 2014), and that obesity promotes the differentiation of adipocytes in WAT, it is possible that obesity may also stimulate marrow adipogenesis at the cost of osteoblast differentiation. This would result in the altered quality of the obese patient's bones, even if elevated mechanical strain may be giving rise to increased BMD.

In addition, obesity is often associated with chronic inflammation. Obese individuals have an altered hormonal milieu and higher circulating levels of pro-inflammatory cytokines. Such cytokines may serve to modify the activity of the osteoclast receptor activator of NF- $\kappa$ B (RANK)/RANK-Ligand (RANKL), thereby increasing osteoclastogenesis and bone resorption. In addition, the bioavailable 25 hydroxyvitamin D3 is decreased in obese individuals, likely due to storage within the excess adipose tissue, which compromises bone mineral content (Cândido and Bressan 2014). Amongst the obese population, there is also an increase in circulating bone-anabolic hormones. This includes higher levels of pancreatic hormones (insulin, amylin, and preptin), and adipose-derived factors including aromatase, leptin, and resistin (Karra and Batterham 2010).

On the other end of the weight spectrum, anorexia patients also exhibit a disease-bone phenotype, with greater fracture propensity. This serious psychiatric disorder manifests in emaciation of the self-starved individual (Dede, et al. 2014). Alongside serious weight deficit, the anorexic patient further suffers from bone structural deficits, such that, the skeletal mechanical capability is impaired. These individuals experience decreased cortical radius thickness and wider endocortical diameters (Dede et al. 2014). Such micro-architectural alterations increase susceptibility to bone fragility, regardless of documented BMD values. These structural defects persist even after recovery from the disease (Dede et al. 2014). In a similar fashion to the long-suffering anorexia patient, low-calorie intake during early stages of life (*i.e.* during skeletal development) results in decreased bone mass, increased fracture risk and osteoporosis in adulthood (Devlin et al. 2010). These defects are most harmful during adolescence when bone accrual is paramount for the development of peak bone mass. As previously discussed, anorexia (and caloric restriction) are associated with increased MAT (Fazeli, et al. 2013; Scheller and Rosen 2014). To date, over 10 distinct animal studies have found increased MAT during states of CR or starvation, such that MAT significantly increases in the proximal femur and tibia of CR mice in comparison to the control mice (Cawthorn et al. 2014; Devlin et al. 2010). Furthermore, CR in young mice decreased serum leptin and IGF-1 levels. Despite elevated bone resorption and decreased bone formation and percentage body fat, MAT was significantly increased in CR mice (Devlin et al. 2010), suggesting that increased MAT is associated with impaired skeletal maturity; however, CR in rabbits causes bone loss without MAT expansion, suggesting that the latter is not necessary for the former (Cawthorn et al 2016). In addition to decreased circulating levels of leptin and IGF-1 during CR, decreased circulating oestradiol and increased circulating FGF21, ghrelin and cortisol/corticosterone levels have also been linked to elevated BM adiposity; thus, each of these factors has been

suggested as mediators of MAT expansion during CR (Cawthorn et al. 2014; Devlin et al. 2010; Shen, et al. 2012; Suchacki, et al. 2016; Sulston and Cawthorn 2016; Syed, et al. 2008; Thompson, et al. 2004). These studies highlight the possibility that MAT may be responsible for endocrine signalling such that the propensity of fracture for the anorexic sufferer is increased. One key question is whether the highly energetic cost of fracture repair, coupled with emaciated status of the anorexic individual, promotes the differentiation of skeletal stem/stromal cells towards MAT to act as an 'emergency storage' of adipocytes, and thus energy, to facilitate survival during self-starvation? If so, this likely comes at the expense of osteoblasts, derived from the same skeletal progenitor, thereby further potentiating bone fragility in anorexic patients.

#### **IV) Pancreatic disease:**

Given the recently acknowledged bone-pancreas loop in the regulation of glucose metabolism by insulin (Faenza, et al. 2015), it is possible that pancreatic diseases such as pancreatitis or pancreatic cancer may result in altered bone homeostasis and/or endocrine function. Studies both *in vitro* and *in vivo* have revealed the osteogenic nature of insulin, promoting cell proliferation, collagen synthesis and uptake of glucose. Insulin acts on bone by binding to the insulin receptor situated on the osteoblast. Recent studies (Ferron, et al. 2010; Fulzele, et al. 2010) have revealed that osteoblast-specific insulin receptor knockout results in decreased osteoblast numbers and bone formation, coupled with reduced OCN activity. Patients with pancreatitis suffer from the loss of exocrine and endocrine functions via inflammatory processes that cause the destruction of the pancreas. Concomitantly, a loss of islet cells ( $\alpha$  and  $\beta$  cells) results in a decrease in the release of glucoregulatory hormones (glucagon, insulin and pancreatic polypeptides). This compromised insulin release is likely to also compromise

osteoblast-endocrine signalling to the insulin receptor. Indeed, a study by Moran et al. (1997) revealed that patients with pancreatic insufficiency, a product of chronic pancreatitis, exhibited osteopenia and osteoporosis, although they were unable to determine the pathological mechanisms underpinning this relationship. Furthermore, preptin, a peptide hormone cosecreted by pancreatic  $\beta$ cells with insulin and amylin has been shown to be anabolic to bone *in vitro* and *in vivo* (Cornish, et al. 2007). During osteoporosis, preptin levels are diminished, positively correlating with BMD. It is understood that preptin is involved in the pathogenesis of osteoporosis through bone formation rather than resorption. However, further studies are required to clarify whether preptin can be a new target for treating osteoporosis by promoting bone formation (Li, et al. 2013).

#### **V) Liver disease:**

The prevalence of patients with chronic liver disease experiencing fracture is estimated at 40% (Nakchbandi 2014). Since the liver coordinates many key metabolic pathways, it is unsurprising that the experience of disease within this organ results in atypical metabolism: liver disease itself is the secondary leading cause of osteoporosis. However, there is a lack of epidemiological data to support the true extent of osteoporosis amongst chronic liver disease sufferers (Nakchbandi 2014). The liver is central to the maintenance of health processes in the individual. For example, the liver secretes bone-health-associated factors, including IGF-I and fibronectin. In health, liver-secreted fibronectin circulates prior to infiltrating the bone matrix: upon infiltration, matrix mineralisation and subsequent microarchitectural properties of bone are favourably promoted. In addition, the liver is capable of acting as a target molecule for bone-active hormones, responding with the production of various endocrine molecules including IL-6. IL-6 can act directly to activate osteoclasts or can serve to stimulate RANKL

production via osteoblasts, such that osteoclasts are indirectly activated. Further, the liver is capable of metabolising bone-active molecules, including OCN, such that the period of bioavailability is reduced. Yet, in disease states, such as non-alcoholic fatty liver disease, IL-6 is upregulated as a by-product of liver injury and attempted consequential liver regeneration: this increase, in turn, promotes bone resorption by active osteoclasts. Furthermore, in chronic liver disease states, a reported 92% of patients have vitamin D deficiency: as such, calcium is liberated from the bone via osteoclastic resorption to retain homeostasis within the blood. The net result of this is the loss of bone (Nakchbandi 2014).


## **Perspective**

The last decade has witnessed growing understanding of the skeleton's ability to act as an endocrine organ. Significant developments in cellular systems and mouse models have revealed increasingly convincing evidence in favour of the skeleton's endocrine function (Figure 3). This adds further credence in reinforcing the importance of the skeleton for survival beyond its mechanical roles. It makes sense, from an evolutionary perspective, that the skeleton produces hormones that regulate skeletal mineralisation, cooperating with other endocrine organs to control the metabolism of phosphate and calcium.

Despite the significant advances in comprehending skeletal energy homeostasis, many questions remain unanswered. Putative investigations of other bone-secreted factors (such as NPP1 and PHOSHPO1) have revealed further candidates for links in metabolic health, including significant roles in diabetes and obesity pathology. Yet much remains to be identified about the specific mechanisms of action and novel pathways of these new


candidates with regard to skeletal and metabolic homeostasis. Continued identification of bone-secreted factors and their function will aid in answering the questions of how and why bone-specific regulation of energy metabolism arose. Most recently, lipocalin (LCN2), an adipokine once thought to be exclusively secreted by adipose tissue has been shown to be an osteoblast-rich, secreted protein. LCN2 crosses the blood-brain barrier to activate the melanocortin 4 receptor, resulting in appetite suppression. Murine loss- and gain-of-function experiments demonstrated that LCN2 maintains glucose homeostasis, improve glucose tolerance and insulin sensitivity, however, more compelling human data is required to fully establish the role of LCN2 (Mosialou, et al. 2017) (Figure 3).

Indeed, little is also known about the role of formation and function of MAT – does MAT contribute to the global regulation of energy metabolism by the skeleton? Does MAT provide a local reservoir of energy for bone-specific cells during bone remodelling or in pathological situations? Further understanding of the mechanisms involved in this bone-metabolic axis will have many diverse implications for the management of T2DM, metabolic syndrome, and other diseases of bone and adipose physiology. Such knowledge will reveal unidentified mechanisms that regulate energy homeostasis, thereby allowing development of novel pharmacological approaches for managing and treating skeletal and metabolic diseases, underscoring the need for continued research into the endocrine and metabolic functions of the skeleton.



**Figure 1. Bone anatomy and composition**

Bone is organised into two distinct structures, cortical and trabecular. Cortical bone accounts for 80% of the skeletal mass and is highly organised, consisting of concentric lamellae arranged in *Haversian* systems. Trabecular, or 'spongy' bone, possesses ten times the surface area of cortical bone, accounting for 20% of the bone mass and enabling bone to withstand compressive and tensile forces. The bone contains osteoblasts, osteocytes, and osteoclasts. Osteoblasts constitute approximately 5% of all bone cells and are the specialised 'bone-building' cells, originating from pluripotent mesenchymal stem cells (MSCs). Following matrix deposition and mineralisation, osteoblasts either remain on the surface of the bone as inactive lining cells; undergo apoptosis; or become entombed by their secreted matrix and differentiate into osteocytes. Osteocytes reside within the mineralised bone matrix and are organised in functional syncytia collectively referred to as the *osteocytic lacunar–canalicular system*. Osteoclasts are derived from the haematopoietic lineage and are responsible for the resorption of mineralised bone and, in partnership with osteoblasts, regulate remodelling of bone tissue. The bone marrow further provides the haematopoietic niche, which supports the survival, self-renewal, and differentiation of the haematopoietic stem cell (HSC). HSCs are capable of differentiation into two cell types: firstly, the common myeloid progenitor, which further differentiates to give rise to a number of blood cells including platelets, eosinophils, basophils, neutrophils, monocytes, and erythrocytes; and secondly, the common lymphoid progenitor, which further differentiates to form B- and T-cells of the immune system. Within the bone marrow cavity, maintenance of the haematopoietic niche is orchestrated through vascular niches, which balance quiescence of HSC, proliferation and also regeneration following injury to the bone marrow. This regulation of HSC homeostasis involves intrinsic and extrinsic signals from the niche, including bound or secreted molecules, contractile force, or even temperature. Haematological malignancies, or chemotherapy/radiation as a treatment for the disease, causes a limit to the regenerative and differentiation potentials of HSCs, causing a functional deficit (further discussed within text – see 'Disease and Bone' section).




**Figure 2 Regulators of bone volume, muscle mass, subcutaneous and marrow adipose**

**tissue.**

(Arrow key: Red solid – increased; green solid – decreased)

Schematic representation of the key regulators of bone volume, muscle mass, subcutaneous and marrow adipose tissue. It is interesting to highlight that both calorie restriction and glucocorticoids result in the loss of adipose tissue, muscle and bone (discussed further in the text).





**Figure 3 Integrative model of the regulation of the new endocrine functions bone, muscle, and marrow adipose tissue.**

(Arrow key: Black solid – accepted; black dashed – speculative; red – inhibitory)

Insulin secretion from the pancreas acts upon the insulin receptor on the osteoblast, which subsequently inhibits Forkhead box protein O 1 (*FoxO1*) expression and suppresses twist basic helix-loop-helix transcription factor 2 (*Twist2*), favouring bone resorption via osteoclast activation. The adipocyte derived hormone leptin has been shown to have two opposing roles, acting centrally to inhibit bone mass accrual and peripherally, increasing osteoblast number and activity. The acidic pH generated in the resorption lacunae decarboxylates OCN on its three glutamic acid residues (GLU13, GLU17 and GLU20) which enable it to be released from the bone matrix into the general circulation. Once circulating, OCN can regulate global energy metabolism via the stimulation of insulin secretion and  $\beta$ -cell proliferation in the pancreas; energy expenditure by muscle; and insulin sensitivity in adipose tissue, muscle, and liver. Furthermore, OCN favours hippocampal development in offspring; brain function in adults; and male fertility by stimulating testosterone synthesis in leydig cells of the testis. A bone-muscle feed forward axis exists where systemic under-carboxylated OCN signals to myofibers favouring uptake and subsequent catabolism of glucose and fatty acids, facilitating physical adaptation to exercise and release of exercise-induced IL-6. The latter drives the

production of bioactive OCN. Adiponectin release from bone marrow adipose tissue may act to indirectly increase bioactive OCN via suppressing osteoblast proliferation, potentially favouring osteoclast activity. Another possibility is that excess local OCN production is responsible, at least in part, for elevated adiponectin production from MAT, however, this remains unclear.

Declaration of interest: There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding: This work was supported by the Medical Research Council (grant numbers (MR/M021394/1); The Biotechnology and Biological Sciences Research Council (BBSRC) in the form of an Institute Strategic Programme Grant (BB/J004316/1;BBS/E/D/20221657); A Wellcome Trust Investigator Award (100981/z/13/z).

Acknowledgements: None.

## **References**

- Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, et al. 2004 PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. *J Clin Invest* **113** 846-855.
- Atlas ID 2016 IDF Diabetes Atlas
- Badman MK & Flier JS 2007 The adipocyte as an active participant in energy balance and metabolism. *Gastroenterology* **132** 2103-2115.
- Bataille R, Delmas PD, Chappard D & Sany J 1990 Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. *Cancer* **66** 167-172.

567 Brown JP, Delmas PD, Malaval L, Edouard C, Chapuy MC & Meunier PJ 1984 Serum bone  
 568 Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. *Lancet* **1**  
 569 1091-1093.

570 Buckley MF, Loveland KA, McKinstry WJ, Garson OM & Goding JW 1990 Plasma cell  
 571 membrane glycoprotein PC-1: cDNA cloning of the human molecule, amino acid sequence,  
 572 and chromosomal location. *Journal of Biological Chemistry* **265** 17506-17511.

573 Caers J, Deleu S, Belaid Z, De Raeve H, Van Valckenborgh E, De Bruyne E, Defresne MP, Van  
 574 Riet I, Van Camp B & Vanderkerken K 2007 Neighboring adipocytes participate in the bone  
 575 marrow microenvironment of multiple myeloma cells. *Leukemia* **21** 1580-1584.

576 Cahill GF, Jr. 2006 Fuel metabolism in starvation. *Annu Rev Nutr* **26** 1-22.

577 Cairns JR & Price PA 1994 Direct demonstration that the vitamin K-dependent bone Gla  
 578 protein is incompletely gamma-carboxylated in humans. *J Bone Miner Res* **9** 1989-1997.

579 Cândido FG & Bressan J 2014 Vitamin D: Link between Osteoporosis, Obesity, and Diabetes?  
 580 *International Journal of Molecular Sciences* **15** 6569-6591.

581 Cao J, Ou G, Yang N, Ding K, Kream BE, Hamrick MW, Isales CM & Shi XM 2015 Impact of  
 582 targeted PPARgamma disruption on bone remodeling. *Mol Cell Endocrinol* **410** 27-34.

583 Cawthorn WP, Scheller EL, Learman BS, Parlee SD, Simon BR, Mori H, Ning X, Bree AJ, Schell  
 584 B, Broome DT, et al. 2014 Bone marrow adipose tissue is an endocrine organ that contributes  
 585 to increased circulating adiponectin during caloric restriction. *Cell Metab* **20** 368-375.

586 Chambers JC, Loh M, Lehne B, Drong A, Kriebel J, Motta V, Wahl S, Elliott HR, Rota F, Scott  
 587 WR, et al. 2015 Epigenome-wide association of DNA methylation markers in peripheral blood  
 588 from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study.  
 589 *Lancet Diabetes Endocrinol* **3** 526-534.

590 Chen J, Shi Y, Regan J, Karuppaiah K, Ornitz DM & Long F 2014 Osx-Cre targets multiple cell  
591 types besides osteoblast lineage in postnatal mice. *PLoS One* **9** e85161.

592 Coe LM, Irwin R, Lippner D & McCabe LR 2011 The bone marrow microenvironment  
593 contributes to type I diabetes induced osteoblast death. *J Cell Physiol* **226** 477-483.

594 Cornish J, Callon KE, Bava U, Watson M, Xu X, Lin JM, Chan VA, Grey AB, Naot D, Buchanan  
595 CM, et al. 2007 Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in  
596 vitro and in vivo. *Am J Physiol Endocrinol Metab* **292** E117-122.

597 Cortes VA & Fernandez-Galilea M 2015 Lipodystrophies: adipose tissue disorders with severe  
598 metabolic implications. *J Physiol Biochem* **71** 471-478.

599 Crockett JC, Rogers MJ, Coxon FP, Hocking LJ & Helfrich MH 2011 Bone remodelling at a  
600 glance. *J Cell Sci* **124** 991-998.

601 Dallas SL & Bonewald LF 2010 Dynamics of the transition from osteoblast to osteocyte. *Ann*  
602 *N Y Acad Sci* **1192** 437-443.

603 Dayeh T, Tuomi T, Almgren P, Perfilyev A, Jansson PA, de Mello VD, Pihlajamaki J, Vaag A,  
604 Groop L, Nilsson E, et al. 2016 DNA methylation of loci within ABCG1 and PHOSPHO1 in  
605 blood DNA is associated with future type 2 diabetes risk. *Epigenetics* **11** 482-488.

606 Dede AD, Lyritis GP & Tournis S 2014 Bone disease in anorexia nervosa. *Hormones (Athens)*  
607 **13** 38-56.

608 Devlin MJ, Cloutier AM, Thomas NA, Panus DA, Lotinun S, Pinz I, Baron R, Rosen CJ &  
609 Bouxsein ML 2010 Caloric restriction leads to high marrow adiposity and low bone mass in  
610 growing mice. *J Bone Miner Res* **25** 2078-2088.

611 Doucette CR, Horowitz MC, Berry R, MacDougald OA, Anunciado-Koza R, Koza RA & Rosen  
612 CJ 2015 A High Fat Diet Increases Bone Marrow Adipose Tissue (MAT) But Does Not Alter  
613 Trabecular or Cortical Bone Mass in C57BL/6J Mice. *J Cell Physiol* **230** 2032-2037.

614 Faienza MF, Luce V, Ventura A, Colaianni G, Colucci S, Cavallo L, Grano M & Brunetti G 2015  
615 Skeleton and glucose metabolism: a bone-pancreas loop. *Int J Endocrinol* **2015** 758148.

616 Fazeli PK, Horowitz MC, MacDougald OA, Scheller EL, Rodeheffer MS, Rosen CJ & Klibanski  
617 A 2013 Marrow fat and bone--new perspectives. *J Clin Endocrinol Metab* **98** 935-945.

618 Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P & Karsenty G 2010  
619 Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. *Cell* **142**  
620 296-308.

621 Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simoes MJ & Cerri PS 2015 Biology of Bone Tissue:  
622 Structure, Function, and Factors That Influence Bone Cells. *Biomed Res Int* **2015** 421746.

623 Fukunaga T, Zou W, Rohatgi N, Colca JR & Teitelbaum SL 2015 An Insulin-Sensitizing  
624 Thiazolidinedione, Which Minimally Activates PPAR $\gamma$ , Does Not Cause Bone Loss. *J Bone*  
625 *Miner Res* **30** 481-488.

626 Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, Faugere MC, Aja S, Hussain  
627 MA, Bruning JC, et al. 2010 Insulin receptor signaling in osteoblasts regulates postnatal bone  
628 acquisition and body composition. *Cell* **142** 309-319.

629 Georgiou KR, Scherer MA, Fan CM, Cool JC, King TJ, Foster BK & Xian CJ 2012 Methotrexate  
630 chemotherapy reduces osteogenesis but increases adipogenic potential in the bone marrow. *J*  
631 *Cell Physiol* **227** 909-918.

632 Gregg EW, Mangione CM, Cauley JA, Thompson TJ, Schwartz AV, Ensrud KE & Nevitt MC  
633 2002 Diabetes and incidence of functional disability in older women. *Diabetes Care* **25** 61-67.

634 Gunaratnam K, Vidal C, Gimble JM & Duque G 2014 Mechanisms of palmitate-induced  
635 lipotoxicity in human osteoblasts. *Endocrinology* **155** 108-116.

636 Guntur AR & Rosen CJ 2012 Bone as an endocrine organ. *Endocr Pract* **18** 758-762.

637 Guntur AR & Rosen CJ 2013 IGF-1 regulation of key signaling pathways in bone. *Bonekey Rep*  
638 **2** 437.

639 Hadjidakis DJ & Androulakis, II 2006 Bone remodeling. *Ann N Y Acad Sci* **1092** 385-396.

640 Holtrop ME & King GJ 1977 The ultrastructure of the osteoclast and its functional  
641 implications. *Clin Orthop Relat Res* 177-196.

642 Huesa C, Zhu D, Glover JD, Ferron M, Karsenty G, Milne EM, Millan JL, Ahmed SF,  
643 Farquharson C, Morton NM, et al. 2014 Deficiency of the bone mineralization inhibitor NPP1  
644 protects mice against obesity and diabetes. *Dis Model Mech* **7** 1341-1350.

645 Huttunen P, Hirvonen J & Kinnula V 1981 The occurrence of brown adipose tissue in outdoor  
646 workers. *Eur J Appl Physiol Occup Physiol* **46** 339-345.

647 Janghorbani M, Feskanich D, Willett WC & Hu F 2006 Prospective study of diabetes and risk  
648 of hip fracture: the Nurses' Health Study. *Diabetes Care* **29** 1573-1578.

649 Johansson H, Kanis JA, Oden A, McCloskey E, Chapurlat RD, Christiansen C, Cummings SR,  
650 Diez-Perez A, Eisman JA, Fujiwara S, et al. 2014 A meta-analysis of the association of fracture  
651 risk and body mass index in women. *J Bone Miner Res* **29** 223-233.

652 Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T & Kassem M 2001 Adipocyte  
653 tissue volume in bone marrow is increased with aging and in patients with osteoporosis.  
654 *Biogerontology* **2** 165-171.

655 Karra E & Batterham RL 2010 The role of gut hormones in the regulation of body weight and  
656 energy homeostasis. *Mol Cell Endocrinol* **316** 120-128.

657 Karsenty G & Ferron M 2012 The contribution of bone to whole-organism physiology. *Nature*  
658 **481** 314-320.

659 Karsenty G, Kronenberg HM & Settembre C 2009 Genetic control of bone formation. *Annu Rev*  
660 *Cell Dev Biol* **25** 629-648.

661 Karsenty G & Olson EN 2016 Bone and Muscle Endocrine Functions: Unexpected Paradigms  
662 of Inter-organ Communication. *Cell* **164** 1248-1256.

663 Lecka-Czernik B 2010 Aleglitazar, a dual PPARalpha and PPARgamma agonist for the  
664 potential oral treatment of type 2 diabetes mellitus. *IDrugs* **13** 793-801.

665 Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD,  
666 Jung DY, et al. 2007 Endocrine regulation of energy metabolism by the skeleton. *Cell* **130** 456-  
667 469.

668 Li N, Zheng YB, Han J, Liang W, Wang JY, Zhou JR, Shen Y & Zhang J 2013 Lower circulating  
669 preptin levels in male patients with osteoporosis are correlated with bone mineral density and  
670 bone formation. *BMC Musculoskelet Disord* **14** 49.

671 Mackenzie NC, Huesa C, Rutsch F & MacRae VE 2012 New insights into NPP1 function:  
672 lessons from clinical and animal studies. *Bone* **51** 961-968.

673 Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, Spencer S, Grupe A,  
674 Henzel W, Stewart TA, et al. 1995 Membrane glycoprotein PC-1 and insulin resistance in non-  
675 insulin-dependent diabetes mellitus. *Nature* **373** 448-451.

676 McCabe LR 2007 Understanding the pathology and mechanisms of type I diabetic bone loss.  
677 *J Cell Biochem* **102** 1343-1357.

678 Mera P, Laue K, Ferron M, Confavreux C, Wei J, Galan-Diez M, Lacampagne A, Mitchell SJ,  
679 Mattison JA, Chen Y, et al. 2016a Osteocalcin Signaling in Myofibers Is Necessary and  
680 Sufficient for Optimum Adaptation to Exercise. *Cell Metab* **23** 1078-1092.

681 Mera P, Laue K, Wei J, Berger JM & Karsenty G 2016b Osteocalcin is necessary and sufficient  
682 to maintain muscle mass in older mice. *Mol Metab* **5** 1042-1047.

683 Michalakis K, Mintziori G, Kaprara A, Tarlatzis BC & Goulis DG 2013 The complex interaction  
684 between obesity, metabolic syndrome and reproductive axis: a narrative review. *Metabolism*  
685 **62** 457-478.

686 Misra M & Klibanski A 2013 Anorexia nervosa, obesity and bone metabolism. *Pediatr*  
687 *Endocrinol Rev* **11** 21-33.

688 Moerman EJ, Teng K, Lipschitz DA & Lecka-Czernik B 2004 Aging activates adipogenic and  
689 suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of  
690 PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. *Aging Cell* **3** 379-  
691 389.

692 Mosialou I, Shikhel S, Liu J-M, Maurizi A, Luo N, He Z, Huang Y, Zong H, Friedman RA,  
693 Barasch J, et al. 2017 MC4R-dependent suppression of appetite by bone-derived lipocalin 2.  
694 *Nature* **advance online publication**.

695 Nakchbandi IA 2014 Osteoporosis and fractures in liver disease: Relevance, pathogenesis and  
696 therapeutic implications. *World Journal of Gastroenterology : WJG* **20** 9427-9438.

697 Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV & Ferrari SL 2016  
698 Mechanisms of diabetes mellitus-induced bone fragility. *Nat Rev Endocrinol*.

699 Nubel T & Ricquier D 2006 Respiration under control of uncoupling proteins: Clinical  
700 perspective. *Horm Res* **65** 300-310.

701 Oldknow K, Morton N, Yadav M, Rajoanah S, Huesa C, Bunger L, Ball D, Ferron M, Karsenty  
702 G & MacRae V 2013 PHOSPHO1: recognition of roles beyond skeletal mineralization. In  
703 *Journal of Bone and Mineral Research: WILEY-BLACKWELL* 111 RIVER ST, HOBOKEN 07030-  
704 5774, NJ USA.

705 Oldknow KJ, MacRae VE & Farquharson C 2015 Endocrine role of bone: recent and emerging  
706 perspectives beyond osteocalcin. *J Endocrinol* **225** R1-19.



707 Oury F, Ferron M, Huizhen W, Confavreux C, Xu L, Lacombe J, Srinivas P, Chamouni A,  
 708 Lugani F, Lejeune H, et al. 2013 Osteocalcin regulates murine and human fertility through a  
 709 pancreas-bone-testis axis. *J Clin Invest* **123** 2421-2433.

710 Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, Hermo L, Suarez S, Roth BL,  
 711 Ducy P, et al. 2011 Endocrine regulation of male fertility by the skeleton. *Cell* **144** 796-809.

712 Palermo A, Tuccinardi D, Defeudis G, Watanabe M, D'Onofrio L, Lauria Pantano A, Napoli  
 713 N, Pozzilli P & Manfrini S 2016 BMI and BMD: The Potential Interplay between Obesity and  
 714 Bone Fragility. *International Journal of Environmental Research and Public Health* **13** 544.

715 Pichardo JC, Trindade AA, Brindle JM & Bolch WE 2007 Method for estimating skeletal  
 716 spongiosa volume and active marrow mass in the adult male and adult female. *J Nucl Med* **48**  
 717 1880-1888.

718 Plantalech L, Guillaumont M, Vergnaud P, Leclercq M & Delmas PD 1991 Impairment of  
 719 gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women. *J Bone*  
 720 *Miner Res* **6** 1211-1216.

721 Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B & Shaughnessy JD,  
 722 Jr. 2008 Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL  
 723 production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in  
 724 multiple myeloma. *Blood* **112** 196-207.

725 Ramsay DS & Woods SC 2014 Clarifying the roles of homeostasis and allostasis in  
 726 physiological regulation. *Psychol Rev* **121** 225-247.

727 Regard JB, Zhong Z, Williams BO & Yang Y 2012 Wnt signaling in bone development and  
 728 disease: making stronger bone with Wnts. *Cold Spring Harb Perspect Biol* **4**.

729 Roberts SJ, Stewart AJ, Sadler PJ & Farquharson C 2004 Human PHOSPHO1 exhibits high  
 730 specific phosphoethanolamine and phosphocholine phosphatase activities. *Biochem J* **382** 59-  
 731 65.

732 Roodman GD 2010 Pathogenesis of myeloma bone disease. *J Cell Biochem* **109** 283-291.

733 Rosen CJ, Ackert-Bicknell C, Rodriguez JP & Pino AM 2009 Marrow fat and the bone  
 734 microenvironment: developmental, functional, and pathological implications. *Crit Rev*  
 735 *Eukaryot Gene Expr* **19** 109-124.

736 Rosen ED & Spiegelman BM 2014 What we talk about when we talk about fat. *Cell* **156** 20-44.

737 Sayols-Baixeras S, Subirana I, Lluís-Ganella C, Civeira F, Roquer J, Do AN, Absher D, Cenarro  
 738 A, Munoz D, Soriano-Tarraga C, et al. 2016 Identification and validation of seven new loci  
 739 showing differential DNA methylation related to serum lipid profile: an epigenome-wide  
 740 approach. The REGICOR study. *Hum Mol Genet.*

741 Scheller EL, Doucette CR, Learman BS, Cawthorn WP, Khandaker S, Schell B, Wu B, Ding SY,  
 742 Bredella MA, Fazeli PK, et al. 2015 Region-specific variation in the properties of skeletal  
 743 adipocytes reveals regulated and constitutive marrow adipose tissues. *Nat Commun* **6** 7808.

744 Scheller EL & Rosen CJ 2014 What's the matter with MAT? Marrow adipose tissue,  
 745 metabolism, and skeletal health. *Ann N Y Acad Sci* **1311** 14-30.

746 Schilling AF, Schinke T, Munch C, Gebauer M, Niemeier A, Priemel M, Streichert T, Rueger  
 747 JM & Amling M 2005 Increased bone formation in mice lacking apolipoprotein E. *J Bone Miner*  
 748 *Res* **20** 274-282.

749 Schwartz AV, Hillier TA, Sellmeyer DE, Resnick HE, Gregg E, Ensrud KE, Schreiner PJ,  
 750 Margolis KL, Cauley JA, Nevitt MC, et al. 2002 Older women with diabetes have a higher risk  
 751 of falls: a prospective study. *Diabetes Care* **25** 1749-1754.

752 Shen W, Scherzer R, Gantz M, Chen J, Punyanitya M, Lewis CE & Grunfeld C 2012  
753 Relationship between MRI-Measured Bone Marrow Adipose Tissue and Hip and Spine Bone  
754 Mineral Density in African-American and Caucasian Participants: The CARDIA Study. *The*  
755 *Journal of Clinical Endocrinology & Metabolism* **97** 1337-1346.

756 Suchacki KJ, Cawthorn WP & Rosen CJ 2016 Bone marrow adipose tissue: formation, function  
757 and regulation. *Curr Opin Pharmacol* **28** 50-56.

758 Sugiyama T, Price JS & Lanyon LE 2010 Functional adaptation to mechanical loading in both  
759 cortical and cancellous bone is controlled locally and is confined to the loaded bones. *Bone* **46**  
760 314-321.

761 Sulston RJ & Cawthorn WP 2016 Bone marrow adipose tissue as an endocrine organ: close to  
762 the bone? *Horm Mol Biol Clin Investig* **28** 21-38.

763 Syed FA, Oursler MJ, Hefferanm TE, Peterson JM, Riggs BL & Khosla S 2008 Effects of estrogen  
764 therapy on bone marrow adipocytes in postmenopausal osteoporotic women. *Osteoporos Int*  
765 **19** 1323-1330.

766 Terpos E, Berenson J, Raje N & Roodman GD 2014 Management of bone disease in multiple  
767 myeloma. *Expert Rev Hematol* **7** 113-125.

768 Thompson NM, Gill DA, Davies R, Loveridge N, Houston PA, Robinson IC & Wells T 2004  
769 Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism  
770 independent of the type 1a growth hormone secretagogue receptor. *Endocrinology* **145** 234-242.

771 Vaananen HK, Zhao H, Mulari M & Halleen JM 2000 The cell biology of osteoclast function. *J*  
772 *Cell Sci* **113 ( Pt 3)** 377-381.

773 Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K & Delmas PD 1997  
774 Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture  
775 in elderly women: the EPIDOS Study. *J Clin Endocrinol Metab* **82** 719-724.

776 Walker RE, Lawson MA, Buckle CH, Snowden JA & Chantry AD 2014 Myeloma bone disease:  
777 pathogenesis, current treatments and future targets. *Br Med Bull* **111** 117-138.

778 Wei J, Shimazu J, Makinistoglu MP, Maurizi A, Kajimura D, Zong H, Takarada T, Iezaki T,  
779 Pessin JE, Hinoi E, et al. 2015 Glucose Uptake and Runx2 Synergize to Orchestrate Osteoblast  
780 Differentiation and Bone Formation. *Cell* **161** 1576-1591.

781 Wu J, Boström P, Sparks LM, Ye L, Choi JH, Giang A-H, Khandekar M, Nuutila P, Schaart G,  
782 Huang K, et al. 2012 Beige Adipocytes are a Distinct Type of Thermogenic Fat Cell in Mouse  
783 and Human. *Cell* **150** 366-376.

784 Xi H, An R, Li L, Wang G, Tao Y & Gao L 2016 Myeloma bone disease: Progress in  
785 pathogenesis. *Prog Biophys Mol Biol* **122** 149-155.

786 Zoch ML, Abou DS, Clemens TL, Thorek DL & Riddle RC 2016 In vivo radiometric analysis  
787 of glucose uptake and distribution in mouse bone. *Bone Res* **4** 16004.

788

789